A Phase 1 healthy volunteer trial of EXS74539
Latest Information Update: 21 Aug 2024
At a glance
- Drugs EXS 74539 (Primary)
- Indications Acute myeloid leukaemia; Cancer; Small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 15 Aug 2024 According to an Exscientia media release, the company plans to submit IND later this year.
- 10 Oct 2023 New trial record
- 03 Oct 2023 According to an Exscientia media release, the company plans to submit IND in the first quarter of 2024 and initiate phase I healthy volunteer trial in in the first half of 2024.